Sort by
Previous Page Page 1 of 34 Next Page
  1. Review

    Emerging therapies for breast cancer

    HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall sur...

    Xichun Hu, Wei Huang and Minhao Fan

    Journal of Hematology & Oncology 2017 10:98

    Published on: 28 April 2017

  2. Review

    Immunotherapy in genitourinary malignancies

    Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination chemotherapies...

    Kathan Mehta, Keyur Patel and Rahul A. Parikh

    Journal of Hematology & Oncology 2017 10:95

    Published on: 24 April 2017

  3. Review

    Recent advances of highly selective CDK4/6 inhibitors in breast cancer

    Uncontrolled cell division is the hallmark of cancers. Full understanding of cell cycle regulation would contribute to promising cancer therapies. In particular, cyclin-dependent kinases 4/6 (CDK4/6), which ar...

    Hanxiao Xu, Shengnan Yu, Qian Liu, Xun Yuan, Sridhar Mani, Richard G. Pestell and Kongming Wu

    Journal of Hematology & Oncology 2017 10:97

    Published on: 24 April 2017

  4. Review

    The use of immunotherapy in the treatment of melanoma

    Patients with advanced melanoma have a compromised anti-tumor immune response leading to tumor immune tolerance and a tumor microenvironment conducive to disease progression. Immunotherapy that successfully ov...

    Tala Achkar and Ahmad A. Tarhini

    Journal of Hematology & Oncology 2017 10:88

    Published on: 24 April 2017

  5. Review

    Immunotherapy in hematologic malignancies: past, present, and future

    The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatme...

    Annie Im and Steven Z. Pavletic

    Journal of Hematology & Oncology 2017 10:94

    Published on: 24 April 2017

  6. Review

    The next generation of immunotherapy: keeping lung cancer in check

    Lung cancer is the deadliest malignancy with more cancer deaths per year than the next three cancers combined. Despite remarkable advances in targeted therapy, advanced lung cancer patients have not experience...

    Ashwin Somasundaram and Timothy F. Burns

    Journal of Hematology & Oncology 2017 10:87

    Published on: 24 April 2017

  7. Research

    A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1

    Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and tumor recurrence and metastasis are major factors that contribute to the poor outcome of patients with HCC. Long noncoding R...

    Wen Ni, Yuqin Zhang, Zetao Zhan, Feng Ye, Yonghao Liang, Jing Huang, Keli Chen, Longhua Chen and Yi Ding

    Journal of Hematology & Oncology 2017 10:91

    Published on: 19 April 2017

  8. Research

    DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma

    The B cell maturation process involves multiple steps, which are controlled by relevant pathways and transcription factors. The understanding of the final stages of plasma cell (PC) differentiation could provi...

    Dalia Quwaider, Luis A. Corchete, Irena Misiewicz-Krzeminska, María E. Sarasquete, José J. Pérez, Patryk Krzeminski, Noemí Puig, María Victoria Mateos, Ramón García-Sanz, Ana B. Herrero and Norma C. Gutiérrez

    Journal of Hematology & Oncology 2017 10:92

    Published on: 18 April 2017

  9. Review

    Emerging therapies for acute myeloid leukemia

    Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely ...

    Caner Saygin and Hetty E. Carraway

    Journal of Hematology & Oncology 2017 10:93

    Published on: 18 April 2017

  10. Research

    Characterization and risk estimate of cancer in patients with primary Sjögren syndrome

    The purpose of this study is to characterize the risk of cancer in a large cohort of patients with primary Sjögren syndrome (SjS).

    Pilar Brito-Zerón, Belchin Kostov, Guadalupe Fraile, Daniel Caravia-Durán, Brenda Maure, Francisco-Javier Rascón, Mónica Zamora, Arnau Casanovas, Miguel Lopez-Dupla, Mar Ripoll, Blanca Pinilla, Eva Fonseca, Miriam Akasbi, Gloria de la Red, Miguel-Angel Duarte-Millán, Patricia Fanlo…

    Journal of Hematology & Oncology 2017 10:90

    Published on: 17 April 2017

  11. Research

    Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs

    Estrogen and progesterone are potent breast mitogens. In addition to steroid hormones, multiple signaling pathways input to estrogen receptor (ER) and progesterone receptor (PR) actions via posttranslational e...

    Todd P. Knutson, Thu H. Truong, Shihong Ma, Nicholas J. Brady, Megan E. Sullivan, Ganesh Raj, Kathryn L. Schwertfeger and Carol A. Lange

    Journal of Hematology & Oncology 2017 10:89

    Published on: 17 April 2017

  12. Review

    The diagnosis and management of NK/T-cell lymphomas

    Extranodal natural killer (NK)/T-cell lymphoma is an aggressive malignancy of putative NK-cell origin, with a minority deriving from the T-cell lineage. Pathologically, the malignancy occurs in two forms, extr...

    Eric Tse and Yok-Lam Kwong

    Journal of Hematology & Oncology 2017 10:85

    Published on: 14 April 2017

  13. Rapid communication

    Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas

    Trabectedin has recently been approved in the USA and in Europe for advanced soft-tissue sarcoma patients who have been treated with anthracycline-based chemotherapy without success. The mechanism of action of...

    Audrey Laroche, Vanessa Chaire, François Le Loarer, Marie-Paule Algéo, Christophe Rey, Kevin Tran, Carlo Lucchesi and Antoine Italiano

    Journal of Hematology & Oncology 2017 10:84

    Published on: 11 April 2017

  14. Research

    Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia

    Chronic lymphocytic leukemia (CLL) is a highly genetically heterogeneous disease. Although CLL has been traditionally considered as a mature B cell leukemia, few independent studies have shown that the genetic...

    Miguel Quijada-Álamo, María Hernández-Sánchez, Cristina Robledo, Jesús-María Hernández-Sánchez, Rocío Benito, Adrián Montaño, Ana E. Rodríguez-Vicente, Dalia Quwaider, Ana-África Martín, María García-Álvarez, María Jesús Vidal-Manceñido, Gonzalo Ferrer-Garrido, María-Pilar Delgado-Beltrán, Josefina Galende, Juan-Nicolás Rodríguez, Guillermo Martín-Núñez…

    Journal of Hematology & Oncology 2017 10:83

    Published on: 11 April 2017

  15. Research

    Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

    Dendritic cells (DCs) enhance the quality of anti-tumor immune response in patients with cancer. Thus, we posit that DC-based immunotherapy, in conjunction with toll-like receptor (TLR)-3 agonist poly-ICLC, is...

    Shikhar Mehrotra, Carolyn D. Britten, Steve Chin, Elizabeth Garrett-Mayer, Colleen A. Cloud, Mingli Li, Gina Scurti, Mohamed L. Salem, Michelle H. Nelson, Melanie B. Thomas, Chrystal M. Paulos, Andres M. Salazar, Michael I. Nishimura, Mark P. Rubinstein, Zihai Li and David J. Cole

    Journal of Hematology & Oncology 2017 10:82

    Published on: 7 April 2017

  16. Research

    Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma

    Pharmacological inhibition of B cell receptor (BCR) signaling has recently emerged as an effective approach in a wide range of B lymphoid neoplasms. However, despite promising clinical activity of the first Br...

    P. Balsas, A. Esteve-Arenys, J. Roldán, L. Jiménez, V. Rodríguez, J. G. Valero, A. Chamorro-Jorganes, R. Puig de la Bellacasa, J. Teixidó, A. Matas-Céspedes, A. Moros, A. Martínez, E. Campo, A. Sáez-Borderías, J. I. Borrell, P. Pérez-Galán…

    Journal of Hematology & Oncology 2017 10:80

    Published on: 31 March 2017

  17. Research

    Integrated analysis identifies microRNA-195 as a suppressor of Hippo-YAP pathway in colorectal cancer

    With persistent inconsistencies in colorectal cancer (CRC) miRNAs expression data, it is crucial to shift toward inclusion of a “pre-laboratory” integrated analysis to expedite effective precision medicine and...

    Min Sun, Haibin Song, Shuyi Wang, Chunxiao Zhang, Liang Zheng, Fangfang Chen, Dongdong Shi, Yuanyuan Chen, Chaogang Yang, Zhenxian Xiang, Qing Liu, Chen Wei and Bin Xiong

    Journal of Hematology & Oncology 2017 10:79

    Published on: 29 March 2017

  18. Review

    Chimeric antigen receptor T cells: a novel therapy for solid tumors

    The chimeric antigen receptor T (CAR-T) cell therapy is a newly developed adoptive antitumor treatment. Theoretically, CAR-T cells can specifically localize and eliminate tumor cells by interacting with the tu...

    Shengnan Yu, Anping Li, Qian Liu, Tengfei Li, Xun Yuan, Xinwei Han and Kongming Wu

    Journal of Hematology & Oncology 2017 10:78

    Published on: 29 March 2017

  19. Review

    The cell cycle checkpoint inhibitors in the treatment of leukemias

    The inhibition of the DNA damage response (DDR) pathway in the treatment of cancers has recently reached an exciting stage with several cell cycle checkpoint inhibitors that are now being tested in several cli...

    A. Ghelli Luserna di Rora’, I. Iacobucci and G. Martinelli

    Journal of Hematology & Oncology 2017 10:77

    Published on: 29 March 2017

  20. Review

    The role of stromal cancer-associated fibroblasts in pancreatic cancer

    Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer generally refractory to conventional treatments. Cancer-associated fibroblasts (CAFs) are cellular components of the desmoplastic stroma characteristi...

    Dagny von Ahrens, Tushar D. Bhagat, Deepak Nagrath, Anirban Maitra and Amit Verma

    Journal of Hematology & Oncology 2017 10:76

    Published on: 28 March 2017

  21. Research

    The antiproliferative ELF2 isoform, ELF2B, induces apoptosis in vitro and perturbs early lymphocytic development in vivo

    ELF2 (E74-like factor 2) also known as NERF (new Ets-related factor), a member of the Ets family of transcription factors, regulates genes important in B and T cell development, cell cycle progression, and angiog...

    Fiona H. X. Guan, Charles G. Bailey, Cynthia Metierre, Patrick O’Young, Dadi Gao, Teh Liane Khoo, Jeff Holst and John E. J. Rasko

    Journal of Hematology & Oncology 2017 10:75

    Published on: 28 March 2017

  22. Research

    Thrombus leukocytes exhibit more endothelial cell-specific angiogenic markers than peripheral blood leukocytes do in acute coronary syndrome patients, suggesting a possibility of trans-differentiation: a comprehensive database mining study

    Current angiogenic therapies for cancers and cardiovascular diseases have not yet achieved expected benefits, which reflects the need for improved understanding of angiogenesis. In this study, we focused on so...

    Hangfei Fu, Nish Vadalia, Eric R. Xue, Candice Johnson, Luqiao Wang, William Y. Yang, Claudette Sanchez, Jun Nelson, Qian Chen, Eric T. Choi, Jian-Xing Ma, Jun Yu, Hong Wang and Xiaofeng Yang

    Journal of Hematology & Oncology 2017 10:74

    Published on: 23 March 2017

Previous Page Page 1 of 34 Next Page
JHO logo